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COMPLICATIONS IN LIVER TRANSPLANTATION 
CMV Infection in Liver Transplantation Under Cyclosporine or 
FK 506 Immunosuppression 
M. Alessiani, S. Kusne, J.J. Fung, J. Torre-Cisneros, A. Jain, K. Abu-Elmagd, S. Takaya, U. Cillo, 
M. Martin, S. Todo, and T.E. Starzl 
THE herpesvirus family is a frequent cause of infectious 
1. complications after liver transplantation. 1.2 In partic-
ular, cytomegalovirus (CMV) infection has been identified 
in our historical series as the most frequent infection seen 
either under cyclosporine (CyA)- or FK 506-based immu-
nosuppression. J.4 
A direct comparison between these two immunosup-
pressive regimens ha.s been addressed as part of a random-
ized trial. allowing us to determine whether there are any 
differences in terms of the incidence and characteristics of 
CMV infection in patients immunosuppressed with either 
FK 506 or CyA. 
MATERIALS AND METHODS 
The characteristics of the study population. the immunosuppres-
sive protocol. and the viral prophylaxis utilized are summarized in 
Table I. 
Briefly. a total of 110 adults underwent onhotopic liver trans-
plantation and were enrolled in this trial. The age. gender. 
duration of follow-up time. origina! liver disease. antimicrobial 
prophylaxis regimens utilized. and the frequency of various da-
nor/recipient CMV serologic matches were comparable in the two 
groups. The minimum duration of follow-up time was 6 months. 
CyA and FK 506 were administered initially as a constant infusion 
at the dosage shown in Table 1. Conversion to the oral route was 
accomplished as soon as it was feasible. Both groups received 
baseline steroid treatment and similar therapy for rejection (when 
necessary) consisting of augmented steroids andlor OKTI. The 
Table 1. Patient Population Under Study 
CyA FK506 
Patient population 
No. patients 53 57 
Sex (WF) 33120 31/26 
Mean age (y) 43.5 42.0 
Mean follow-up (d) 342 341 
One-year survival ("to) 86 96 
Immunosuppl'8fl8Ne protOCol 
IV continuous infusion (mgIkg per day) 4 0.1 
PO dose every 12 hours (mgIkg) 8 0.15 
Viral prophytaxis 
Oral acyclovir from 400 to 3200 mg for 6 
months in both groups 
patients treated with CyA with uncontrolled rejection were 
switched to FK 506. 
Only symptomatic CMV infections were considered for this 
study. Primary infection was defined by isolation of CMV from 
clinical specimens with seroconversion. Viral syndrome was 
defined as isolation of CMV in a patient with temperature eleva-
tion > 38°C for at least I week. without any other identifiable agent 
being recognized as a potential cause for the syndrome. Localized 
CMV disease was defined as tissue invasion of a single organ 
determined either histopathologically or by culture of the virus 
from the tissue. Disseminated CMV disease was defined as tissue 
involvement of two or more noncontiguous sites. 
Routine viral surveillance was accomplished by scheduled 
cultures and serologic detenninations at 2-week intervals for the 
first 2 months. and then once a month for the duration of the 
follow-up. Additional clinical evaluations were obtained when 
symptomatic disease was suspected. 
Statistical analysis was based on the intention to treat. Propor-
tions were analyzed using the chi-square test of association. 
RESULTS 
Of the 110 patients enrolled in this study, 10 died during 
the follow-up period. None of the deaths occurring in 
either group were a result of a CMV infection. The I-year 
survival rate was 86% for the CyA group and 96% for the 
FK 506 group. 
Symptomatic CMV infection was diagnosed in 21 pa-
tients. In the CyA group, 11 of 53 patients (20.8%) devel-
oped a total number of 15 episodes of symptomatic CMV 
infection. The number of episodes per infected patient in 
this group was 1.4. In the FK 506 group, 10 of 57 patients 
(17.5%) developed a total of to different CMV infections. 
In this group, the number of episodes per patients was one. 
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T8bIe 2. RMa Met SIte of InfeCtIon In CyA- .... 
FK 5O&-T,.... PatIentS 
CyAln- 53) F1( 506 (n - 57) 
ResuI\s 
0/0 Patients infected 2O.S 17.5 
Total episodeS 15 10 
Epi80deIinfected patient 1.4 1 
Site of occurrence 
Syndrome 2 1 
GastritIs 4 3 
Hepatitis 4 3 
Retinitis 1 0 
Mulllpleorgans 3 3 
Vasculitis 0 
The sites of occurrence for each single episode are sum-
marized in the Table 2. As shown in this table. the most 
frequent site of infection were the liver and the GI tract. 
Multiple organs were involved in each group on three 
occasions. 
Analysis of the donor and recipient CMV serology 
demonstrated in both Cy A and FK 506 groups that both 
the seronegative and the seropositive recipients had a 
greater risk of symptomatic CMV disease if their donor 
was seropositive. Of the 63 seropositive recipients. 33 
received a liver from 8. seronegative donor. Only 1 of these 
recipients (3%) developed a clinical CMV infection com-
pared to 8 (26.7%) of the 30 patients that received an organ 
from a seropositive donor. The remaining 47 recipients 
were seronegative. In 25 of these. the donor was also 
seronegative. Only 2 (8%) had symptomatic CMV. For the 
other 22 patients. the donor was seropositive. The inci-
dence of CMV infection in this group was dramatically 
increased. with 10 patients (45.5%) experiencing a clinical 
CMV infection. 
The intluence of retransplantation and the use of OKT3 
were evaluated also. Retransplantation was performed in 8 
patients under Cy A and 4 patients under FK 506 treat-
ment. In the Cy A group, CMV infection was diagnosed in 
9 of the 45 patients that received one transplant (20%) and 
in 2 of the 8 who were retransplanted (25%). In the FK 506 
grouP. a single transplant was associated with a frequency 
of CMV infection of 13.2% (7 of 53 patients), while the rate 
of CMV infection in the retransplant cases increased to 
75% (3 of4 patients). In this last group, the difference was 
statistically significant (P = .0142) (Fig 1). 
OKTI was used in 17 patients receiving Cy A, 5 of whom 
developed a clinical CMV infection (29.4%). In the FK 
group. 10 patients received OKT3 and 3 experienced a 
CMV infection (30%). For both groups, the rate of CMV in 
patients not receiving OKT3 was reduced by 50% as 
compared to those who did (Fig 2). 
Of particular interest was the finding that within the Cy A 
group, CMV infection was associated with other types of 
infection in 9 patients (82%. II infected cases total). In the 
FK 506 group, this happened in only 5 of 10 cases (50%) 
(NS). 
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Fig 1. The rate of CMV infection increased dramatically an6 
retransplantation in the FK 506 group. in the CyA group, the 
difference is minimal. 
Thirty-seven patients in the CyA group were switched to 
FK 506 for persistent rejection. Nine of these had a CMV 
infection (82% of the patients infected in the overall Cy A 
group). The CMV infection occurred either just before or 
immediately after the switch in 5 of the 9 patients. Only 1 
patient in the FK 506 group was converted to CyA. In this 
case, a multipie-organ CMV infection was evident while 
the patient was still on FK 506. As expected. most of these 
"switch-over" patients experienced a very complicated 
postoperative course, with several episodes of rejection. 
liver failure. retransplantation. having a requirement of 
'K ... 
FIg 2. The use of OKT3 Increased !he incidence of symptomatiC 
CUY infection by 50% in both CyA and FK 506 groups. 
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high doses of steroids. and the use of OKTI before the 
conversion. 
DISCUSSION 
CMV infection is one of the more frequent causes of 
morbidity in immunocompromised patients. particularly 
those having received either a solid organ or bone marrow 
transplant.5-7 Our previous experience with liver trans-
plantation confirms this statement. In a population of 101 
liver transplant recipients immunosuppressed with CyA 
and steroids. 22% developed a symptomatic CMV infec-
tion.3 At that time. no specific immunoprophylaxis or 
therapy for CMV infection was available. 
More recently, a similar population of 110 patients. 
treated with FK 506 and low-dose steroids. was studied.4 
In this group. high doses of acyclovir were used for viral 
prophylaxis. and DHPG (gancyclovir) was available as a 
therapeutic agent for CMV infection. In spite of these 
differences between the two series. the frequency of CMV 
infection remained the same (21%). Nevertheless. an im-
portant difference was noted: infections were no longer life 
threatening to the same degree as before. In the initial 
series. CMV caused the death of five patients while in the 
later series. none of the patients died as a result of a CMV 
infection. 
In the current randomized study. the frequency of CMV 
infection (19%) and its severity (no deaths due to CMV) 
are quite comparable to those obtained in our initial 
series.4 No statistical difference was seen between the 
CyA and the FK 506 group in terms of the frequency of 
CMV infection and the site of occurrence. However. the 
FK 506 population experienced a lower number of epi-
sodes of symptomatic CMV (to vs 15) than did the CyA 
group. 
In this randomized trial. a high incidence of patients 
were converted from Cy A to FK 506. This may confuse 
the interpretation of the results. since some of them 
developed their CMV infection after the switch. Review of 
the immunosuppressive course of the patients revealed 
that patients who developed symptomatic CMV infection 
after conversion from Cy A to FK 506 were considered 
overimmunosuppressed. It is unlikely that FK 506 alone 
was responsible for the CMV infection in these patients. 
Fig 3 shows the difference between the two groups in 
terms of their requirement for additional immunosuppres-
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Fig 3. The requirement for additional immunosuppression was 
higher in the CyA group. This overimmunosuppression was nee-
eSS8l'f to control the rejection. 
sion. The higher incidence of bacterial and fungal infec-
tions in patients who received augmented immunosuppres-
sion suggests that these patients are at higher risk for all 
infections. If the baseline immunosuppressive regimen is 
able to reduce the requirement of the augmented immuno-
suppression. a reduced frequency of CMV infection might 
be anticipated. However. this hypothesis was not entirely 
verified in the randomized study. It appears that other 
factors. such as donor and recipient serology. play an 
important role. 
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